Notice of republication
This article was republished on April 8, 2021, to correct errors in the Data Availability Statement that were introduced during the typesetting process. The publisher apologizes for the errors. Please download this article again to view the correct version. The originally published, uncorrected article and the republished, corrected articles are provided here for reference.
Supporting information
S1 File. Originally published, uncorrected article.
(PDF)
Click here for additional data file. (2.9MB, pdf)
S2 File. Republished, corrected article.
(PDF)
Click here for additional data file. (2.9MB, pdf)
Reference
- 1.Frame S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E, et al. (2020) Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS ONE 15(7): e0234103. 10.1371/journal.pone.0234103 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
S1 File. Originally published, uncorrected article.
(PDF)
Click here for additional data file. (2.9MB, pdf)
S2 File. Republished, corrected article.
(PDF)
Click here for additional data file. (2.9MB, pdf)